- Home
- NSSC vs GHRS Comparison
NSSC vs GHRS Comparison
Compare NSSC & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NSSC
- GHRS
- Stock Information
- Founded
- NSSC 1969
- GHRS 2018
- Country
- NSSC United States
- GHRS Ireland
- Employees
- NSSC N/A
- GHRS N/A
- Industry
- NSSC Telecommunications Equipment
- GHRS Biotechnology: Pharmaceutical Preparations
- Sector
- NSSC Telecommunications
- GHRS Health Care
- Exchange
- NSSC Nasdaq
- GHRS Nasdaq
- Market Cap
- NSSC 899.1M
- GHRS 960.2M
- IPO Year
- NSSC N/A
- GHRS 2021
- Fundamental
- Price
- NSSC $30.42
- GHRS $14.50
- Analyst Decision
- NSSC Strong Buy
- GHRS Strong Buy
- Analyst Count
- NSSC 6
- GHRS 8
- Target Price
- NSSC $34.50
- GHRS $30.63
- AVG Volume (30 Days)
- NSSC 259.2K
- GHRS 336.4K
- Earning Date
- NSSC 08-25-2025
- GHRS 09-02-2025
- Dividend Yield
- NSSC 1.85%
- GHRS N/A
- EPS Growth
- NSSC N/A
- GHRS N/A
- EPS
- NSSC 1.22
- GHRS N/A
- Revenue
- NSSC $181,227,000.00
- GHRS N/A
- Revenue This Year
- NSSC N/A
- GHRS N/A
- Revenue Next Year
- NSSC $6.02
- GHRS N/A
- P/E Ratio
- NSSC $24.82
- GHRS N/A
- Revenue Growth
- NSSC N/A
- GHRS N/A
- 52 Week Low
- NSSC $19.00
- GHRS $6.00
- 52 Week High
- NSSC $58.09
- GHRS $20.50
- Technical
- Relative Strength Index (RSI)
- NSSC 55.53
- GHRS 48.15
- Support Level
- NSSC $29.55
- GHRS $12.81
- Resistance Level
- NSSC $30.91
- GHRS $19.51
- Average True Range (ATR)
- NSSC 0.70
- GHRS 1.50
- MACD
- NSSC -0.14
- GHRS -0.31
- Stochastic Oscillator
- NSSC 36.92
- GHRS 25.22
About NSSC NAPCO Security Technologies Inc.
NAPCO Security Technologies Inc manufactures security products, encompassing access control systems, door-locking products, intrusion and fire alarm systems and video surveillance products. Its products are used for various applications which includes alarm systems like automatic communicators, combination control panels/digital communicators and digital keypad systems, fire alarm control panel and area detectors mainly used for commercial, residential, institutional, industrial and governmental uses. Geographically, the company derives a majority of its revenue from the United States.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.